Ketorolac
Ketorolac has been studied in 1 paper since 2017: none in people yet, 1 review. No study of it in people or animals has been published yet. The newest paper, Aug 9, 2017: “From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy”.
“During SNP administration, CVC was similar at the ketorolac site (0.005-50 mM, all P > 0.05) relative to Control”
1 of its findings points the other way.
- 1 lab in 1 country
- 1 finding against
- 4 trials, none about aging
- Funders: National Heart, Lung, and Blood Institute and 1 more
What did studies of Ketorolac find?
1Studies of Ketorolac measured 1 outcome; the most studied are cutaneous vascular conductance (1 study).
Cutaneous vascular conductance
upin humans1no changein humans1
1 study
Cutaneous vascular conductance
upin humans1no changein humans1
Ketorolac increases cutaneous vascular conductance in humans.
“In older adults, ketorolac increased CVC relative to Control during 0.005-0.05 mM SNP administration (all P < 0.05)”
Human trialDuring 0.005–0.05 mM sodium nitroprusside administration in older adultsforearm skin10 mMn = 10
American journal of physiology. Regulatory, integrative and comparative physiology
Ketorolac has no effect on cutaneous vascular conductance in humans.
“During SNP administration, CVC was similar at the ketorolac site (0.005-50 mM, all P > 0.05) relative to Control”
Human trialDuring 0.005–50 mM sodium nitroprusside administration in young adultsforearm skin10 mMn = 10
American journal of physiology. Regulatory, integrative and comparative physiology
Trial sponsors
Company1 trialPhase 116 people
1 trialPhase 2137 people
Icahn School of Medicine at Mount Sinai
1 trialPhase 160 people